A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2012; epublished August 30, 2012).
Latest News
RIS: what are the risk factors for CIS/MS?
December 26, 2012There has been little information on the natural history of radiologically isolated syndrome (RIS) since it was first described in 2009 (Okuda et al. Neurology 2009;72:800-805).
Fingolimod effective in all subgroups: analysis of phase III data
December 18, 2012REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 –
An analysis of data from the phase III FREEDOMS and TRANSFORMS trials indicates that oral fingolimod produces significant reductions in the rates of relapse and disease progression in subgroups of patients with different levels of disease activity (Havrdova et al. ECTRIMS 2011; abstract P473).
Targeting glutamate: the end of the monoamine hypothesis?
December 5, 2012A number of recent papers have focused attention on the remarkable responses seen with glutamatergic agents in major depressive disorder (MDD), raising questions about the monoamine hypothesis of psychiatric disorders that has dominated biological psychiatry for a half century (Schildkraut JJ. Am J Psychiatry 1965;122:509-522).